Baird Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $57

Benzinga Newsdesk www.benzinga.com Positive 54.6%

Neg 0% Neu 0% Pos 54.6%

Baird analyst Jack Allen initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $57.